Glyscend Therapeutics announces initiation of phase 1 clinical trial on the heels of preclinical data presented at #EASD2021 on the metabolic benefits of its oral polymer-based duodenal exclusion therapy
Phase 1 clinical trial currently underway in Australia investigating a noninvasive, oral polymer therapy that dramatically improves glucose homeostasis with weight loss in nonclinical models. Glyscend, Inc. delivered an oral…